Does a common EB gel raise or lower cancer risk? 5-year study aims to find out.

NCT ID NCT06423573

First seen Nov 01, 2025 · Last updated May 09, 2026 · Updated 33 times

Summary

This study follows 580 people with dystrophic or junctional epidermolysis bullosa (EB) for up to 5 years. Researchers will compare those who use Filsuvez gel with those who don't, to see if the gel affects the chance of developing skin cancer. The goal is to gather safety data, not to test a new treatment.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for EPIDERMOLYSIS BULLOSA, DYSTROPHIC are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • CHU de Toulouse, Hôpital Larrey

    RECRUITING

    Toulouse, France

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Guy's and St Thomas' NHS Foundation Trust

    RECRUITING

    London, United Kingdom

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Hospital Clinic, Barcelona

    RECRUITING

    Barcelona, Spain

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

  • Hospital San Juan de Dios (Barcelona)

    RECRUITING

    Barcelona, Spain

    Contact Email: •••••@•••••

    Contact

  • Hospital of Skin and Venereal Diseases of Thessaloniki

    RECRUITING

    Thessaloniki, Greece

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.